Edifoligide and long-term outcomes after coronary artery bypass grafting: PRoject of Ex-vivo Vein graft ENgineering via Transfection IV (PREVENT IV) 5-year results

Background Edifoligide, an E2F transcription factor decoy, does not prevent vein graft failure or adverse clinical outcomes at 1 year in patients undergoing coronary artery bypass grafting (CABG). We compared the 5-year clinical outcomes of patients in PREVENT IV treated with edifoligide and placebo...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	The American heart journal 2012-09, Vol.164 (3), p.379-386.e1
Hauptverfasser:	Lopes, Renato D., MD, PhD, Williams, Judson B., MD, Mehta, Rajendra H., MD, MS, Reyes, Eric M., MS, Hafley, Gail E., MS, Allen, Keith B., MD, Mack, Michael J., MD, Peterson, Eric D., MD, MPH, Harrington, Robert A., MD, Gibson, C. Michael, MD, Califf, Robert M., MD, Kouchoukos, Nicholas T., MD, Ferguson, T. Bruce, MD, Lorenz, Todd J., MD, Alexander, John H., MD, MHS
Format:	Artikel
Sprache:	eng
Schlagworte:	Adolescent Adult Aged Aged, 80 and over Biological and medical sciences Cardiology Cardiology. Vascular system Cardiovascular Clinical outcomes Combined Modality Therapy Coronary Artery Bypass Coronary Artery Disease - drug therapy Coronary Artery Disease - mortality Coronary Artery Disease - surgery Coronary heart disease Coronary vessels Double-Blind Method Follow-Up Studies Heart Heart attacks Humans Kaplan-Meier Estimate Medical sciences Middle Aged Myocardial Infarction - epidemiology Myocardial Revascularization - statistics & numerical data Older people Oligonucleotides - therapeutic use Patient Readmission - statistics & numerical data Postoperative Complications Proportional Hazards Models Surgery (general aspects). Transplantations, organ and tissue grafts. Graft diseases Surgery of the heart Treatment Outcome Young Adult
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!